Correlation Between SAB Biotherapeutics and UroGen Pharma

Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and UroGen Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and UroGen Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SAB Biotherapeutics and UroGen Pharma, you can compare the effects of market volatilities on SAB Biotherapeutics and UroGen Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of UroGen Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and UroGen Pharma.

Diversification Opportunities for SAB Biotherapeutics and UroGen Pharma

-0.56

Correlation Coefficient

SAB Biotherapeutics  UroGen Pharma

Excellent diversification

The 3 months correlation between SAB and UroGen is -0.56. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and UroGen Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on UroGen Pharma and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with UroGen Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of UroGen Pharma has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and UroGen Pharma go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and UroGen Pharma

Assuming the 90 days horizon SAB Biotherapeutics is expected to generate 2.01 times less return on investment than UroGen Pharma. In addition to that, SAB Biotherapeutics is 8.4 times more volatile than UroGen Pharma. It trades about 0.01 of its total potential returns per unit of risk. UroGen Pharma is currently generating about 0.15 per unit of volatility. If you would invest  1,193  in UroGen Pharma on September 4, 2024 and sell it today you would earn a total of  95.00  from holding UroGen Pharma or generate 7.96% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	90.48%
Values	Daily Returns

SAB Biotherapeutics  vs.  UroGen Pharma

SAB Biotherapeutics

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, SAB Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

UroGen Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days UroGen Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, UroGen Pharma is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

Pair Trading with SAB Biotherapeutics and UroGen Pharma

The main advantage of trading using opposite SAB Biotherapeutics and UroGen Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, UroGen Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will offset losses from the drop in UroGen Pharma's long position.

The idea behind SAB Biotherapeutics and UroGen Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.